221 related articles for article (PubMed ID: 25662332)
1. Ibrutinib enhances the antitumor immune response induced by intratumoral injection of a TLR9 ligand in mouse lymphoma.
Sagiv-Barfi I; Kohrt HE; Burckhardt L; Czerwinski DK; Levy R
Blood; 2015 Mar; 125(13):2079-86. PubMed ID: 25662332
[TBL] [Abstract][Full Text] [Related]
2. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors.
Marabelle A; Kohrt H; Sagiv-Barfi I; Ajami B; Axtell RC; Zhou G; Rajapaksa R; Green MR; Torchia J; Brody J; Luong R; Rosenblum MD; Steinman L; Levitsky HI; Tse V; Levy R
J Clin Invest; 2013 Jun; 123(6):2447-63. PubMed ID: 23728179
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral CpG-B Promotes Antitumoral Neutrophil, cDC, and T-cell Cooperation without Reprograming Tolerogenic pDC.
Humbert M; Guery L; Brighouse D; Lemeille S; Hugues S
Cancer Res; 2018 Jun; 78(12):3280-3292. PubMed ID: 29588348
[TBL] [Abstract][Full Text] [Related]
4.
Cheng Y; Lemke-Miltner CD; Wongpattaraworakul W; Wang Z; Chan CHF; Salem AK; Weiner GJ; Simons AL
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33060147
[TBL] [Abstract][Full Text] [Related]
5. Natural killer T cell and TLR9 agonists as mucosal adjuvants for sublingual vaccination with clade C HIV-1 envelope protein.
Singh S; Yang G; Byrareddy SN; Barry MA; Sastry KJ
Vaccine; 2014 Dec; 32(51):6934-6940. PubMed ID: 25444819
[TBL] [Abstract][Full Text] [Related]
6. Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG oligodeoxynucleotide either alone or in combination with poly(I:C) and CD40 ligand plasmid DNA.
Stone GW; Barzee S; Snarsky V; Santucci C; Tran B; Kornbluth RS
J Thorac Oncol; 2009 Jul; 4(7):802-8. PubMed ID: 19550243
[TBL] [Abstract][Full Text] [Related]
7. In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study.
Brody JD; Ai WZ; Czerwinski DK; Torchia JA; Levy M; Advani RH; Kim YH; Hoppe RT; Knox SJ; Shin LK; Wapnir I; Tibshirani RJ; Levy R
J Clin Oncol; 2010 Oct; 28(28):4324-32. PubMed ID: 20697067
[TBL] [Abstract][Full Text] [Related]
8. Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy.
Wang D; Jiang W; Zhu F; Mao X; Agrawal S
Int J Oncol; 2018 Sep; 53(3):1193-1203. PubMed ID: 29956749
[TBL] [Abstract][Full Text] [Related]
9. Novel oligodeoxynucleotide agonists of TLR9 containing N3-Me-dC or N1-Me-dG modifications.
Putta MR; Zhu F; Li Y; Bhagat L; Cong Y; Kandimalla ER; Agrawal S
Nucleic Acids Res; 2006; 34(11):3231-8. PubMed ID: 16798912
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells.
Wang S; Campos J; Gallotta M; Gong M; Crain C; Naik E; Coffman RL; Guiducci C
Proc Natl Acad Sci U S A; 2016 Nov; 113(46):E7240-E7249. PubMed ID: 27799536
[TBL] [Abstract][Full Text] [Related]
11. Soluble β-glucan from Grifola frondosa induces tumor regression in synergy with TLR9 agonist via dendritic cell-mediated immunity.
Masuda Y; Nawa D; Nakayama Y; Konishi M; Nanba H
J Leukoc Biol; 2015 Dec; 98(6):1015-25. PubMed ID: 26297795
[TBL] [Abstract][Full Text] [Related]
12. TLR9 agonist enhances radiofrequency ablation-induced CTL responses, leading to the potent inhibition of primary tumor growth and lung metastasis.
Xu A; Zhang L; Yuan J; Babikr F; Freywald A; Chibbar R; Moser M; Zhang W; Zhang B; Fu Z; Xiang J
Cell Mol Immunol; 2019 Oct; 16(10):820-832. PubMed ID: 30467420
[TBL] [Abstract][Full Text] [Related]
13. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
14. Combination of cyclophosphamide, rituximab, and intratumoral CpG oligodeoxynucleotide successfully eradicates established B cell lymphoma.
Betting DJ; Hurvitz SA; Steward KK; Yamada RE; Kafi K; van Rooijen N; Timmerman JM
J Immunother; 2012 Sep; 35(7):534-43. PubMed ID: 22892450
[TBL] [Abstract][Full Text] [Related]
15. Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity.
Lonsdorf AS; Kuekrek H; Stern BV; Boehm BO; Lehmann PV; Tary-Lehmann M
J Immunol; 2003 Oct; 171(8):3941-6. PubMed ID: 14530311
[TBL] [Abstract][Full Text] [Related]
16. T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy.
Houot R; Levy R
Blood; 2009 Apr; 113(15):3546-52. PubMed ID: 18941113
[TBL] [Abstract][Full Text] [Related]
17. Targeted In Vivo Delivery of NF-κB Decoy Inhibitor Augments Sensitivity of B Cell Lymphoma to Therapy.
Zhang Z; Zhao X; Wang D; Moreira D; Su YL; Alcantara M; Swiderski P; Wong J; Hui S; Forman S; Kwak L; Kortylewski M
Mol Ther; 2021 Mar; 29(3):1214-1225. PubMed ID: 33248246
[TBL] [Abstract][Full Text] [Related]
18. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself.
Li J; Song W; Czerwinski DK; Varghese B; Uematsu S; Akira S; Krieg AM; Levy R
J Immunol; 2007 Aug; 179(4):2493-500. PubMed ID: 17675511
[TBL] [Abstract][Full Text] [Related]
19. CpG oligodeoxynucleotide treatment enhances innate resistance and acquired immunity to African trypanosomes.
Harris TH; Mansfield JM; Paulnock DM
Infect Immun; 2007 May; 75(5):2366-73. PubMed ID: 17339353
[TBL] [Abstract][Full Text] [Related]
20. Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization.
Lemke-Miltner CD; Blackwell SE; Yin C; Krug AE; Morris AJ; Krieg AM; Weiner GJ
J Immunol; 2020 Mar; 204(5):1386-1394. PubMed ID: 31953355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
